BCG, Biomarkers, and Beyond: GU Oncology Research and Treatment Advances скачать в хорошем качестве

BCG, Biomarkers, and Beyond: GU Oncology Research and Treatment Advances

At the Oncology Forum 2025, host Sanjay Juneja, MD, led a dynamic discussion with panelists Tian Zhang, MD, Petros Grivas, MD, PhD, and Karine Tawagi, MD, covering pivotal developments across genitourinary cancers. The panel explored late-breaking data on PARP inhibitors in metastatic castrate-sensitive prostate cancer, BCG-naïve non–muscle-invasive bladder cancer trials like CREST, and the potential of EV/pembrolizumab in metastatic urothelial carcinoma. They also discussed the evolving role of circulating tumor DNA in bladder cancer, five-year survival data from KEYNOTE-564 in renal cell carcinoma, and promising new therapies like casdatifan in RCC. The session highlighted both clinical enthusiasm and emerging questions around treatment sequencing, patient selection, and long-term outcomes.